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Residual beta-cell secretion in type 1 diabetes is commonly assessed by area-under-curve of plasma C-peptide concentration (AUCCpep) following mixed-meal tolerance test (MMTT). We aimed to investigate alternative measures of beta-cell responsiveness. 
Methods 
We analysed data from 32 youth (age 7 to 17years) undergoing MMTT within 6months of type 1 diabetes diagnosis. We related AUCCpep with (i) validated mechanistic index of postprandial beta-cell responsiveness MI accounting for glucose level during MMTT, and (ii) pragmatic marker calculated as baseline plasma C‑peptide concentration corrected for baseline plasma glucose concentration. 
Results
Postprandial responsiveness MI was correlated with age and BMI SDS (Rs=0.66 and 0.44, P<0.01 and P<0.05) and was more correlated with glycated haemoglobin than AUCCpep (Rs=0.79, P=0.04). The pragmatic marker was highly correlated with AUCCpep (Rs=0.94, P<0.01).
Conclusions
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In the present work, we re-analysed MMTT data obtained in newly-diagnosed children and adolescents with type 1 diabetes aged 7 to 17 years ADDIN EN.CITE 2 (i) to identify surrogate mechanistic and pragmatic markers of AUCCpep and (ii) to explore the relationships among demographic and clinical factors, and AUCCpep and its surrogate markers.  

METHODS
We analysed data obtained from 32 participants with newly-diagnosed type 1 diabetes [age 12.4(2.9) years, 12 males, HbA1c 6.8%(1.1), BMI SDS 0.62(1.02), total daily dose of insulin 0.57(0.23) U/kg; mean (SD)] who underwent MMTT within 6 months of diagnosis [mean time since diagnosis 142(38) days] ADDIN EN.CITE 2. The National Research Ethics Committee East of England–Cambridge South approved the study. 
All participants (aged ≥16 years) gave informed consent, and children <16 years gave assent and their parents gave informed consent to the study procedures.
The MMTT was performed following an overnight fast, with no food or drink other than water from midnight, and at baseline glucose levels between 4 and 11.1 mmol/L. Long-acting insulin and basal rates for insulin pump users were continued as normal. The use of rapid-acting insulin bolus was acceptable up to two hours before the MMTT and the use of short-acting insulin bolus up to six hours before the MMTT. Participants ingested 6 ml/kg of BoostTM meal solution (maximum 360 ml), within 10 minutes. Blood samples for the measurement of C-peptide and glucose were collected 10 minutes prior to the meal (-10 min), at the time of ingestion (0 min), and at 15, 30, 60, 90 and 120 minutes.
Plasma C-peptide was assayed in singleton on a Diasorin Liaison® XL automated immunoassay analyser using a one-step chemiluminescence immunoassay (Diasorin S.p.A, 13040 Saluggia (VC), Italy). Glucose levels were analysed via an adaption of the hexokinase-glucose-6-phosphate dehydrogenase method HYPERLINK \l "_ENREF_3" \o "Kunst, 1983 #2703"  ADDIN EN.CITE <EndNote><Cite><Author>Kunst</Author><Year>1983</Year><RecNum>2703</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>2703</rec-number><foreign-keys><key app="EN" db-id="fpwwad0voppwfzex9z3p9e9w0sxa0029rrp2" timestamp="0">2703</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Kunst, A.</author><author>Drager, B.</author><author>Ziegenhorn, J.</author></authors></contributors><titles><title>UV methods with hexokinase and glucose-6-phosphate 456 dehydrogenase</title><secondary-title>Methods of Enzymatic Analysis</secondary-title></titles><pages>163-72</pages><dates><year>1983</year></dates><pub-location>Deerfield FL</pub-location><urls></urls></record></Cite></EndNote>3. HbA1c was analysed on the Tosoh G8 High Performance Liquid Chromatography Analyser using the gold standard ion-exchange method with <2% between-batch imprecision (Tosoh Bioscience, Inc., 6000 Shoreline Court, Suite 101, South San Francisco, USA).
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The Spearman rank correlation coefficient was used to explore relationships between age, BMI SDS (body mass index standard deviation score), HbA1c, total daily dose of insulin, baseline plasma C-peptide, AUCCpep, baseline plasma C‑peptide divided by baseline plasma glucose, IAUCCpep, insulin dose-adjusted A1C (IDAA1C) defined as A1C (percent) + [4 x insulin dose (units per kilogram per 24 h)]  ADDIN EN.CITE 5,  M0 and MI. Fisher’s r-to-z transformation was applied for testing the difference between two Spearman rank correlation coefficients HYPERLINK \l "_ENREF_6" \o "Myers, 2006 #2592"  ADDIN EN.CITE <EndNote><Cite><Author>Myers</Author><Year>2006</Year><RecNum>2592</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>2592</rec-number><foreign-keys><key app="EN" db-id="fpwwad0voppwfzex9z3p9e9w0sxa0029rrp2" timestamp="0">2592</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Myers, Leann </author><author>J. Sirois, Maria </author></authors></contributors><titles><title>Spearman Correlation Coefficients, Differences between</title><secondary-title>Encyclopedia of Statistical Sciences</secondary-title></titles><volume>12</volume><dates><year>2006</year></dates><urls></urls></record></Cite></EndNote>6. P values less than 0.05 were considered statistically significant. As these are post-hoc evaluations, all observations are considered exploratory. Statistical analyses were performed using SPSS, version 21 (IBM Software, Hampshire, UK). Data are reported as mean(SD) or median [interquartile range], unless stated otherwise.

RESULTS
The postprandial and fasting beta-cell responsiveness MI and M0 were estimated at 3.3[1.6-5.4] and at 3.1[2.0-4.5] 10-9/min, respectively. Supplemental material Figure S1 shows a sample model fit to measured plasma C-peptide including measurements of plasma glucose (the forcing function). Figure S2 depicts weighted residuals across all participants demonstrating acceptable fit of the model to plasma C-peptide measurements. 
Table 1 reports the Spearman rank correlation among demographic and clinical factors, AUCCpep and its surrogate markers.  The strongest correlations found for age and BMI SDS were with MI (RS=0.66 and 0.44 respectively, P<0.01 and P<0.05 respectively). The total daily dose of insulin was inversely correlated with M0 (RS=-0.42, P<0.05) and baseline C-peptide over baseline glucose (RS=‑0.38, P<0.05). 
Figure 1 demonstrates that AUCCpep has a stronger correlation with baseline C-peptide corrected for baseline glucose (RS=0.94) than baseline C-peptide per se (RS=0.88). Supplemental material Figure S3 relates baseline HbA1c versus AUCCpep and log-transformed MI.  AUCCpep was not correlated with HbA1c (RS=-0.19, P=NS) whereas MI is (RS=-0.36, P<0.05); the difference between the two correlation coefficients is statistically significant (P=0.04).

DISCUSSION
The present analysis demonstrates the feasibility of using a model of C-peptide kinetics to assess residual beta-cell function during MMTT in newly-diagnosed type 1 diabetes. Traditionally, the AUCCpep during a MMTT has not been corrected for glucose excursions, which are likely to affect the amplitude of the C-peptide response ADDIN EN.CITE 2. Our data show that using more advanced measures of beta-cell function, such as MI and M0, can identify meaningful correlations with clinical parameters such as TDD and HbA1c, which are not identified using uncorrected AUCCpep. In addition, we show baseline C-peptide corrected for baseline glucose to be a surrogate marker of AUCCpep.
The basal responsiveness M0 and the postprandial responsiveness MI were estimated at median 3.3 and median 3.1 10-9/min, respectively. These values are considerably smaller than those estimated in normal subjects where M0 were estimated at a mean of 10.3 and MI at 90.0 10-9/min  ADDIN EN.CITE 7. In two subjects, MI was estimated at zero and in one subject M0 at zero due to the lack of increased C-peptide levels post-meal and undetectable C-peptide level at baseline. These estimations are clinically meaningful as individuals with complete basal and postprandial insulin responsiveness can be identified.  
The positive correlations between age and MI, and between BMI SDS and MI suggest that postprandial responsiveness is more preserved in older and heavier children and adolescents with newly-diagnosed type 1 diabetes than the younger and lighter individuals. 
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We show that MI was more tightly correlated with HbA1c than AUCCpep (P=0.04) indicating that MI may be a more clinically relevant marker of C-peptide secretion than AUCCpep. The study is limited by a relatively small sample size. Further analyses with larger datasets and longitudinal evaluations are warranted. We applied parameters of C-peptide kinetics determined in healthy subjects. As C-peptide is eliminated primarily by the kidney and assuming comparable kidney function among healthy individuals and those with recently diagnosed type 1 diabetes, we consider this limitation to be of little significance to our findings.
Alternative C-peptide secretion models assume a more complex relationship between glucose concentration and insulin secretion compared to the model used in the present study ADDIN EN.CITE ,. These alternative models may provide additional information about C‑peptide secretory characteristics but require more frequent sampling. Our parameter MI represents the dominant relationship between plasma glucose and C-peptide secretion and is accounted for in the alternative approaches ADDIN EN.CITE ,.
In conclusion, baseline C-peptide corrected for baseline glucose may be a suitable surrogate marker of residual beta-cell in newly-diagnosed type 1 diabetes. Postprandial pancreatic responsiveness estimated through a model of C-peptide kinetics appears more relevant to glucose control than the conventional area-under-curve of plasma C-peptide concentration following MMTT.  
Legends of Tables and Figures
Table 1. Spearman rank correlation coefficients between demographic/clinical factors and markers of beta-cell responsiveness (N=32).
Figure 1. The scatter plot of AUCCpep versus baseline C-peptide (left panel) and AUCCpep versus baseline C-peptide corrected for baseline glucose level (right panel).


Table 1. Spearman rank correlation between demographic/clinical factors and markers of beta-cell responsiveness (N=32). 













* P<0.05 **P < 0.01 Significant correlations are shown in boldface 
TDD: total daily dose of insulin
BMI SDS: body mass index standard deviation score
IDAA1c: Insulin-dose adjusted HbA1c
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